Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InSphero Publishes 3D Tumor-Stroma Model for Non-Small Cell Lung Cancer

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
PLOS One article delivers promising co-culture method to mimic tumor microenvironment, demonstrating potential for biomarker and drug discovery.

InSphero AG, working with researchers at the Medical University Innsbruck, has published a study highlighting development of a novel 3D cell culture model for non-small cell lung cancer (NSCLC), one of the leading causes of cancer deaths in men and women worldwide. The findings, published March 24 in PLOS One, used InSphero's Grav1tyPLUSTM hanging drop  platform to form 3D tumor spheroid co-cultures comprised of a NSCLC tumor cell line and lung-derived fibroblasts. The results showed how both lung cancer cells and stromal cells (lung fibroblasts) behave differently when grown together in 3D than when grown alone. 

The study was initiated in response to the recent failure of several targeted therapies for NSCLC in clinical trials, therapies which were supported by promising in vitro data. To achieve a better in vitro model, researchers used the NSCLC cell lines A549 or Colo699 to create 3D tumors in hanging drops, with or without the lung fibroblast cell line SV80. The tumors were then analyzed for viability, morpology, and expression of different phenotypic markers using immunohistochemistry (IHC) and other methods. Most notable were changes in the tumor cells during co-culture that indicated an epithelial to mesenchymal transition (EMT), as evidenced by an increase in vimentin protein expression, and a decrease in the epithelial cell adhesion protein E-cadherin. Also of interest was the expression of alpha smooth muscle actin (a-SMA), a marker of cancer-associated fibroblasts, in the SV80 fibroblasts only when co-cultured with A549 cells. 

Dr. Jens Kelm, Chief Scientific Officer and co-founder of InSphero AG was co-author on the manuscript He states the 3D co-culture model should improve drug efficacy testing by removing some of the bias inherent in current 2D in vitro models used to screen anti-cancer drugs. "What this 3D lung cancer co-culture model confirmed for us is that tumor cells are phenotypically different in terms of their viability, activity, and morphology when they grow in the presence of fibroblasts. Likewise, the stromal cells associated with tumors also behave differently in co-culture than they do alone, becoming more like myofibroblasts, cells that are known to assist tumor growth, invasion, and metastasis. This model creates an even more native in vitro tumor environment to more easily assess tumor growth, pathobiology, and drug efficacy." 

Using Insphero's automation-compatible, high-throughput platform, the authors plan to conduct advanced screens for improved anti-cancer drugs and to indentify novel NSCLC biomarkers.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms
PerkinElmer named as exclusive distributor of InSphero 3D culture technology.
Thursday, August 06, 2015
InSphero AG Secures CHF 20 Million Series C Financing
3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Wednesday, July 15, 2015
InSphero AG Secures CHF 20 Million Series C Financing
Leading 3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Tuesday, July 14, 2015
InSphero Announces Collaboration with NCATS
Study to characterize 460 NCATS anti-cancer agents in 3D tumor models generated using InSphero technology.
Friday, March 21, 2014
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!